BBA
INO icon

BLB&B Advisors’s Inovio Pharmaceuticals INO Stock Holding History

BLB&B Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-954
Closed -$64K – 281
2018
Q3 		$64K Sell
954
-500
-34% -$27.8K 0.01% 295
2018
Q2 		$68K Sell
1,454
-84
-5% -$4.63K 0.01% 296
2018
Q1 		$87K Hold
1,538
– – 0.01% 300
2017
Q4 		$76K Buy
1,538
+261
+20% +$16.2K 0.01% 303
2017
Q3 		$97K Buy
+1,277
New +$95K 0.01% 293

Other funds holding INO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

BLB&B Advisors's INO Position: Q4 2018 in Review

BLB&B Advisors sold out of Inovio Pharmaceuticals (INO) in Q4 2018, closing a stake of 954 shares — an estimated $64K sold.

BLB&B Advisors first reported a position in INO in Q3 2017 and held it in 5 quarters. The position peaked at $97K in Q3 2017. 125 funds tracked by Wall St. Rank hold INO as of Q4 2018.

  • BLB&B Advisors reported no remaining Inovio Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BLB&B Advisors sold 954 Inovio Pharmaceuticals shares in Q4 2018, an estimated $64K.
  • BLB&B Advisors first reported a position in Inovio Pharmaceuticals in Q3 2017 and held it in 5 quarters.
  • BLB&B Advisors's Inovio Pharmaceuticals position peaked at $97K in Q3 2017.
  • 125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2018.

Based on BLB&B Advisors's 13F filing for Q4 2018, filed 17 Jan 2019.